HC Wainwright Lifts Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – HC Wainwright increased their Q3 2026 EPS estimates for Pharming Group in a research note issued to investors on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of $0.23 per share for the quarter, up from their previous forecast of $0.20. HC Wainwright has a “Buy” rating and a $37.00 price objective on the stock. The consensus estimate for Pharming Group’s current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Pharming Group’s Q4 2026 earnings at $0.24 EPS.

Several other brokerages have also recently commented on PHAR. Oppenheimer reaffirmed an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d)” rating on shares of Pharming Group in a research report on Friday, August 7th. Canaccord Genuity Group set a $38.00 target price on Pharming Group in a report on Wednesday, September 23rd. Finally, Zacks Research cut shares of Pharming Group from a “hold” rating to a “strong sell” rating in a research note on Friday, July 31st. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $38.67.

Pharming Group Trading Down 2.0%

Shares of NASDAQ:PHAR opened at $9.75 on Thursday. The stock has a market capitalization of $690.11 million, a price-to-earnings ratio of 81.25 and a beta of -0.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.31 and a current ratio of 3.01. The company has a 50 day moving average price of $11.15 and a 200 day moving average price of $13.28. Pharming Group has a 1-year low of $9.62 and a 1-year high of $21.34.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently bought a new stake in Pharming Group stock. MAC Alpha Capital Management LP purchased a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group accounts for about 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd biggest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V. is a global biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with significant unmet medical needs, using biotechnology and protein-replacement approaches.

Pharming’s commercial products include Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral therapy for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency disorder.